p.96 抽出テキスト

32. Maro EE, Janabi M, Kaushik R. Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. Trop Doct 2006;36:225–227. https://doi.org/10.1258/ 004947506778604904 33. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol 2008;51:1033–1039. https://doi.org/10.1016/j.jacc.2007.10. 055 34. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348: 1639–1646. https://doi.org/10.1056/NEJMoa021737 35. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348: 1647–1655. https://doi.org/10.1056/NEJMoa021715 36. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol 1997;146:385–393. https://doi.org/10.1093/ oxfordjournals.aje.a009291 37. Codd MB, Sugrue DD, Gersh BJ, Melton LJ III. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975– 1984. Circulation 1989;80:564–572. https://doi.org/10.1161/01.CIR.80.3.564 38. Andrews RE, Fenton MJ, Ridout DA, Burch M. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation 2008;117:79–84. https://doi.org/10.1161/CIRCULATIONAHA.106.671735 39. Peters S, Trümmel M, Meyners W. Prevalence of right ventricular dysplasiacardiomyopathy in a non-referral hospital. Int J Cardiol 2004;97:499–501. https://doi. org/10.1016/j.ijcard.2003.10.037 40. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006;296:1593–1601. https://doi.org/10.1001/jama. 296.13.1593 41. Migliore F, Zorzi A, Michieli P, Perazzolo Marra M, Siciliano M, Rigato I, et al. Prevalence of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave inversion at preparticipation screening. Circulation 2012;125:529–538. https://doi.org/ 10.1161/CIRCULATIONAHA.111.055673 42. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchia J, et al. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol 2018;71: 2293–2302. https://doi.org/10.1016/j.jacc.2018.03.462 43. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 2019;140:31–41. https://doi.org/10.1161/CIRCULATIONAHA.118. 037934 44. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374: 233–241. https://doi.org/10.1056/NEJMoa1505517 45. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic landscape of peripartum cardiomyopathy. Circulation 2021;143:1852–1862. https:// doi.org/10.1161/CIRCULATIONAHA.120.052395 46. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995–2017. J Med Genet 2018;55: 261–268. https://doi.org/10.1136/jmedgenet-2017-105080 47. Tini G, Sessarego E, Benenati S, Vianello PF, Musumeci B, Autore C, et al. Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: methodological issues and clinical implications. Eur J Clin Invest 2021;51:e13665. https://doi.org/10.1111/eci.13665 48. Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail 2022;24:2342–2351. https://doi.org/10.1002/ejhf. 2532 49. Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation 2022;146:1123–1134. https://doi.org/10.1161/CIRCULATIONAHA.121. 058457 50. Tiron C, Campuzano O, Fernandez-Falgueras A, Alcalde M, Loma-Osorio P, Zamora E, et al. Prevalence of pathogenic variants in cardiomyopathy-associated genes in myocarditis. Circ Genom Precis Med 2022;15:e003408. https://doi.org/10.1161/CIRCGEN. 121.003408 51. Seidel F, Holtgrewe M, Al-Wakeel-Marquard N, Opgen-Rhein B, Dartsch J, Herbst C, et al. Pathogenic variants associated with dilated cardiomyopathy predict outcome in pediatric myocarditis. Circ Genom Precis Med 2021;14:e003250. https://doi.org/10. 1161/CIRCGEN.120.003250 52. Ammirati E, Raimondi F, Piriou N, Sardo Infirri L, Mohiddin SA, Mazzanti A, et al. Acute myocarditis associated with desmosomal gene variants. JACC Heart Fail 2022;10: 714–727. https://doi.org/10.1016/j.jchf.2022.06.013 53. Cardim N, Freitas A, Brito D. From hypertrophic cardiomyopathy centers to inherited cardiovascular disease centers in Europe. A small or a major step? A position paper from the Nucleus of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology. Rev Port Cardiol 2011;30:829–835. https://doi. org/10.1016/j.repc.2011.09.005 54. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E, Ripoll-Vera T, Evangelista-Masip A, Moya-Mitjans A, et al. Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms. Rev Esp Cardiol 2016;69:300–309. https://doi. org/10.1016/j.recesp.2015.11.031 55. Vriz O, AlSergani H, Elshaer AN, Shaik A, Mushtaq AH, Lioncino M, et al. A complex unit for a complex disease: the HCM-Family Unit. Monaldi Arch Chest Dis 2021;92. https://doi.org/10.4081/monaldi.2021.2147 56. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al. Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology. Virchows Arch 2017;471:691–705. https://doi.org/ 10.1007/s00428-017-2221-0 57. Fellmann F, van El CG, Charron P, Michaud K, Howard HC, Boers SN, et al. European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. Eur J Hum Genet 2019;27:1763–1773. https://doi.org/10.1038/ s41431-019-0445-y 58. de Hosson M, Goossens PJJ, De Backer J, De Wolf D, Van Hecke A. Needs and experiences of adolescents with congenital heart disease and parents in the transitional process: a qualitative study. J Pediatr Nurs 2021;61:90–95. https://doi.org/10.1016/j.pedn. 2021.03.016 59. de Hosson M, De Backer J, De Wolf D, De Groote K, Demulier L, Mels S, et al. Development of a transition program for adolescents with congenital heart disease. Eur J Pediatr 2020;179:339–348. https://doi.org/10.1007/s00431-019-03515-4 60. Tini G, Vianello PF, Rizzola G, La Malfa G, Porto I, Canepa M. Telehealth monitoring for hypertrophic cardiomyopathy and amyloid cardiomyopathy patients: lessons from the coronavirus disease 2019 lockdown in Italy. J Cardiovasc Med 2020;21:622–623. https:// doi.org/10.2459/JCM.0000000000001024 61. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011. In: The European Parliament and the Council of the European Union, (ed); 2011. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:52022DC0210 (5 April 2023 date last accessed). 62. Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:1448–1458. https://doi.org/10.1093/ eurheartj/ehs397 63. Elliott P, Charron P, Blanes JR, Tavazzi L, Tendera M, Konte M, et al. European cardiomyopathy pilot registry: EURObservational research programme of the European Society of Cardiology. Eur Heart J 2016;37:164–173. https://doi.org/10.1093/ eurheartj/ehv497 64. van Velzen HG, Schinkel AFL, Baart SJ, Oldenburg RA, Frohn-Mulder IME, van Slegtenhorst MA, et al. Outcomes of contemporary family screening in hypertrophic cardiomyopathy. Circ Genom Precis Med 2018;11:e001896. https://doi.org/10.1161/ CIRCGEN.117.001896 65. Ranthe MF, Carstensen L, Oyen N, Jensen MK, Axelsson A, Wohlfahrt J, et al. Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons. Circulation 2015;132: 1013–1019. https://doi.org/10.1161/CIRCULATIONAHA.114.013478 66. Gimeno JR, Lacunza J, Garcia-Alberola A, Cerdan MC, Oliva MJ, Garcia-Molina E, et al. Penetrance and risk profile in inherited cardiac diseases studied in a dedicated screening clinic. Am J Cardiol 2009;104:406–410. https://doi.org/10.1016/j.amjcard.2009.03. 055 67. Ploski R, Rydzanicz M, Ksiazczyk TM, Franaszczyk M, Pollak A, Kosinska J, et al. Evidence for troponin C (TNNC1) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome in infancy. Am J Med Genet A 2016;170:3241–3248. https:// doi.org/10.1002/ajmg.a.37860 68. Surmacz R, Franaszczyk M, Pyda M, Ploski R, Bilinska ZT, Bobkowski W. Autosomal recessive transmission of familial nonsyndromic dilated cardiomyopathy due to compound desmoplakin gene mutations. Pol Arch Intern Med 2018;128:785–787. https:// doi.org/10.20452/pamw.4365 69. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368 69a. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627–3639. https://doi.org/10.1093/ eurheartj/ehad195. In press. 70. Bonny A, Lellouche N, Ditah I, Hidden-Lucet F, Yitemben MT, Granger B, et al. C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia. Cardiol Res Pract 2010;2010:919783. https://doi.org/10.4061/2010/919783 71. Donal E, Delgado V, Bucciarelli-Ducci C, Galli E, Haugaa KH, Charron P, et al. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026